- Home
- LPTX vs XBIT Comparison
LPTX vs XBIT Comparison
Compare LPTX & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- XBIT
- Stock Information
- Founded
- LPTX 2011
- XBIT 2005
- Country
- LPTX United States
- XBIT United States
- Employees
- LPTX N/A
- XBIT N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- XBIT Pharmaceuticals and Biotechnology
- Sector
- LPTX Health Care
- XBIT Health Care
- Exchange
- LPTX Nasdaq
- XBIT Nasdaq
- Market Cap
- LPTX 119.6M
- XBIT 105.2M
- IPO Year
- LPTX N/A
- XBIT 2015
- Fundamental
- Price
- LPTX $0.34
- XBIT $3.14
- Analyst Decision
- LPTX Buy
- XBIT
- Analyst Count
- LPTX 2
- XBIT 0
- Target Price
- LPTX $8.00
- XBIT N/A
- AVG Volume (30 Days)
- LPTX 5.9M
- XBIT 38.6K
- Earning Date
- LPTX 03-26-2025
- XBIT 05-09-2025
- Dividend Yield
- LPTX N/A
- XBIT N/A
- EPS Growth
- LPTX N/A
- XBIT N/A
- EPS
- LPTX N/A
- XBIT N/A
- Revenue
- LPTX N/A
- XBIT N/A
- Revenue This Year
- LPTX N/A
- XBIT N/A
- Revenue Next Year
- LPTX N/A
- XBIT N/A
- P/E Ratio
- LPTX N/A
- XBIT N/A
- Revenue Growth
- LPTX N/A
- XBIT N/A
- 52 Week Low
- LPTX $0.28
- XBIT $2.94
- 52 Week High
- LPTX $4.79
- XBIT $9.96
- Technical
- Relative Strength Index (RSI)
- LPTX 33.17
- XBIT 44.89
- Support Level
- LPTX $0.28
- XBIT $3.15
- Resistance Level
- LPTX $0.65
- XBIT $3.31
- Average True Range (ATR)
- LPTX 0.05
- XBIT 0.17
- MACD
- LPTX 0.02
- XBIT -0.02
- Stochastic Oscillator
- LPTX 16.22
- XBIT 21.67
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.